Gary E. Archer

8.6k total citations · 2 hit papers
80 papers, 6.5k citations indexed

About

Gary E. Archer is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Gary E. Archer has authored 80 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 43 papers in Immunology and 21 papers in Molecular Biology. Recurrent topics in Gary E. Archer's work include Immunotherapy and Immune Responses (36 papers), CAR-T cell therapy research (23 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Gary E. Archer is often cited by papers focused on Immunotherapy and Immune Responses (36 papers), CAR-T cell therapy research (23 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Gary E. Archer collaborates with scholars based in United States, Australia and Japan. Gary E. Archer's co-authors include Darell D. Bigner, John H. Sampson, Duane A. Mitchell, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Amy B. Heimberger, Roger E. McLendon, Michael R. Zalutsky and Carol J. Wikstrand and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Gary E. Archer

79 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

2015 410 citations Duane A. Mitchell, Kristen A. Batich et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary E. Archer United States	42	3.7k	3.2k	2.4k	1.8k	923	80	6.5k
Hideho Okada United States	54	4.1k 1.1×	5.1k 1.6×	2.6k 1.1×	2.8k 1.5×	421 0.5×	198	8.8k
Carol J. Wikstrand United States	48	2.7k 0.7×	1.6k 0.5×	2.0k 0.9×	3.3k 1.8×	1.9k 2.1×	105	7.5k
Hiroaki Wakimoto United States	56	3.8k 1.0×	1.3k 0.4×	2.3k 1.0×	4.8k 2.6×	409 0.4×	185	9.4k
Peter Kufer Germany	46	5.1k 1.4×	3.0k 1.0×	407 0.2×	2.2k 1.2×	3.6k 3.9×	113	7.5k
Barbara Murdoch Canada	29	3.2k 0.9×	1.8k 0.6×	1.6k 0.7×	4.9k 2.7×	123 0.1×	51	9.0k
C. Ryan Miller United States	44	2.0k 0.6×	649 0.2×	1.4k 0.6×	3.4k 1.8×	337 0.4×	156	6.3k
Luis Sánchez-Pérez United States	34	2.5k 0.7×	2.3k 0.7×	833 0.4×	1.1k 0.6×	185 0.2×	77	4.0k
Michael A. Curran United States	35	4.0k 1.1×	3.6k 1.1×	274 0.1×	1.7k 0.9×	288 0.3×	127	7.0k
Rosandra N. Kaplan United States	22	3.5k 0.9×	1.9k 0.6×	318 0.1×	2.2k 1.2×	187 0.2×	51	5.7k
Pablo Umaña Switzerland	32	1.8k 0.5×	2.3k 0.7×	678 0.3×	2.4k 1.3×	2.7k 2.9×	119	5.2k

Countries citing papers authored by Gary E. Archer

Since Specialization

Citations

This map shows the geographic impact of Gary E. Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Archer more than expected).

Fields of papers citing papers by Gary E. Archer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Archer. The network helps show where Gary E. Archer may publish in the future.

Co-authorship network of co-authors of Gary E. Archer

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Archer. A scholar is included among the top collaborators of Gary E. Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Archer. Gary E. Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hotchkiss, Kelly, Sarah Cook, Ying Zhou, et al.. (2025). IL-7–mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models. Journal of Clinical Investigation. 135(12). 1 indexed citations

Gedeon, Patrick C., et al.. (2020). GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. PLoS ONE. 15(7). e0236374–e0236374. 3 indexed citations

Evgin, Laura, Amanda L. Huff, Phonphimon Wongthida, et al.. (2020). Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11(1). 3187–3187. 92 indexed citations

Gedeon, Patrick C., Teilo Schaller, Satish K. Chitneni, et al.. (2018). A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research. 24(15). 3611–3631. 38 indexed citations

Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, et al.. (2017). Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research. 23(8). 1898–1909. 242 indexed citations

Nair, Smita K., Gabriel De Leon, David Boczkowski, et al.. (2014). Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. Clinical Cancer Research. 20(10). 2684–2694. 74 indexed citations

Choi, Bryan D., Carter M. Suryadevara, Luis Sánchez-Pérez, et al.. (2014). EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. PLoS ONE. 9(4). e94281–e94281. 96 indexed citations

Dannull, Jens, Nancy Haley, Gary E. Archer, et al.. (2013). Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. Journal of Clinical Investigation. 123(7). 3135–3145. 58 indexed citations

Sánchez-Pérez, Luis, Bryan D. Choi, Gary E. Archer, et al.. (2013). Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE. 8(3). e59082–e59082. 52 indexed citations

10.

Sampson, John H., Robert J. Schmittling, Gary E. Archer, et al.. (2012). A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. PLoS ONE. 7(2). e31046–e31046. 91 indexed citations

11.

Sampson, John H., Amy B. Heimberger, Gary E. Archer, et al.. (2010). Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(31). 4722–4729. 613 indexed citations breakdown →

12.

Sampson, John H., Gary E. Archer, Duane A. Mitchell, et al.. (2009). An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8(10). 2773–2779. 221 indexed citations

13.

Choi, Bryan D., Gary E. Archer, Duane A. Mitchell, et al.. (2009). EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma. Brain Pathology. 19(4). 713–723. 107 indexed citations

14.

Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, & Darell D. Bigner. (2008). Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology. 20(5). 267–275. 128 indexed citations

15.

Fecci, Peter E., Hidenobu Ochiai, Duane A. Mitchell, et al.. (2007). Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. Clinical Cancer Research. 13(7). 2158–2167. 265 indexed citations

16.

Villavicencio, Alan T., Gary E. Archer, Roger E. McLendon, et al.. (1999). Treatment of Neoplastic Meningitis with Intrathecal Temozolomide. Neurosurgery. 45(3). 703–703. 7 indexed citations

17.

Archer, Gary E., John H. Sampson, Roger E. McLendon, et al.. (1999). Intrathecal Busulfan Treatment of Human Neoplastic Meningitis in Athymic Nude Rats. Journal of Neuro-Oncology. 44(3). 233–241. 16 indexed citations

18.

Ashley, David M., John H. Sampson, Gary E. Archer, et al.. (1997). A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. Journal of Neuroimmunology. 78(1-2). 34–46. 27 indexed citations

19.

Pastan, Ira, Gary E. Archer, Roger E. McLendon, et al.. (1995). Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.. Proceedings of the National Academy of Sciences. 92(7). 2765–2769. 29 indexed citations

20.

He, Xuanmin, Gary E. Archer, Carol J. Wikstrand, et al.. (1994). Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. Journal of Neuroimmunology. 52(2). 127–137. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact